Last reviewed · How we verify
NCT06136117: MBOTE-CONTACT
Monkeypox, Biology, Outcome, Transmission and Epidemiology -Prospective Follow-up of High-risk Contacts
trial in Mpox in 257 participants. Completed in 1 October 2024.
1 October 2024
Quick facts
| Lead sponsor | Institute of Tropical Medicine, Belgium |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 257 |
| Start date | 22 May 2023 |
| Primary completion | 1 October 2024 |
| Estimated completion | 1 October 2024 |
| Sites | 1 location across Democratic Republic of the Congo |
Conditions studied
- Mpox — all drugs for Mpox →
Sponsor
Institute of Tropical Medicine, Belgium
Who can join
Eligibility, any sex, with Mpox. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
With the MBOTE-CONTACT study, a detailed follow-up study of high-risk contacts of mpox patients will be done. The MBOTE-CONTACT study will be nested in the NIH-Funded PALM-007 clinical trial (NCT05559099) and the MBOTE project on mpox transmission. The study will take place in Maniema Province, Democratic Republic of Congo (DRC). Participants will be recruited among high-risk contacts of mpox patients included in the PALM-007 trial. Consenting contacts will be either followed daily at the central study site or visited weekly by an outreach team in the community. They will be examined daily for signs and symptoms and asked to provide daily saliva and weekly blood samples for polymerase chain reaction (PCR) and/or serology. If participants develop mpox, they are offered treatment and enrollment in the PALM-007 trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06136117
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Institute of Tropical Medicine, Belgium trials
Trials by the same sponsor.
- NCT07463040 — Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) · Phase 3 · not yet recruiting
- NCT07174648 — Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo. · not yet recruiting
- NCT07499739 — Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX) · Phase 4 · not yet recruiting
- NCT07342829 — Prospective Follow-up After MVA-BN Booster Vaccination · not yet recruiting
- NCT06839989 — An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06136117 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Tropical Medicine, Belgium
- Last refreshed: 7 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06136117.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing